Leen Willems

Dr. Leen Willems


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Neurobiology of Disease
Verified
Journal Article
Open access
SNSofie Nelissen
Sofie Nelissen
TVTim Vangansewinkel
Tim Vangansewinkel
NGNathalie Geurts
Nathalie Geurts
LGLies Geboes
Lies Geboes
ELEvi Lemmens
Evi Lemmens
SHSven Hendrix
Sven Hendrix
Mast cells (MCs) are found abundantly in the central nervous system and play a complex role in neuroinflammatory diseases such as multiple sclerosis and stroke. In the present study, we show that MC-deficient Kit(W-sh/W-sh) mice display significantly increased astrogliosis and T cell infiltration as well as significantly reduced functional recovery after spinal cord injury compared to wildtype mice. In addition, MC-deficient mice show significantly increased levels of MCP-1, TNF-α, IL-10 and IL-13 protein levels in the spinal cord. Mice deficient in mouse mast cell protease 4 (mMCP4), an MC-specific chymase, also showed increased MCP-1, IL-6 and IL-13 protein levels in spinal cord samples and a decreased functional outcome after spinal cord injury. A degradation assay using supernatant from MCs derived from either mMCP4(-/-) mice or controls revealed that mMCP4 cleaves MCP-1, IL-6, and IL-13 suggesting a protective role for MC proteases in neuroinflammation. These data show for the first time that MCs may be protective after spinal cord injury and that they may reduce CNS damage by degrading inflammation-associated cytokines via the MC-specific chymase mMCP4.

1 December 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
YFYanick Fanton
Yanick Fanton
BRBoris Robic
Boris Robic
JRJean-Luc Rummens
Jean-Luc Rummens
ADAnnick Daniëls
Annick Daniëls
SWSeverina Windmolders
Severina Windmolders
MHMarc Hendrikx
Marc Hendrikx

1 August 2016 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
YFYanick Fanton
Yanick Fanton
CHCynthia Houbrechts
Cynthia Houbrechts
LWLeen Willems
Leen Willems
ADAnnick Daniëls
Annick Daniëls
LLLoes Linsen
Loes Linsen
KHKaren Hensen
Karen Hensen

Verified
Journal Article
Open access
PDF file
LWLeen Willems
Leen Willems
ADAnnick Daniëls
Annick Daniëls
YFYanick Fanton
Yanick Fanton
LLLoes Linsen
Loes Linsen
LELize Evens
Lize Evens
MHMarc Hendrikx
Marc Hendrikx
Human cardiac stem cells isolated from atrial appendages based on aldehyde dehydrogenase activity (CASCs) can be expanded in vitro and differentiate into mature cardiomyocytes. In this study, we assess whether Wnt activation stimulates human CASC proliferation, whereas Wnt inhibition induces cardiac maturation. CASCs were cultured as described before. Conventional PCR confirmed the presence of the Frizzled receptors. Small-molecule inhibitors (IWP2, C59, XAV939, and IWR1-endo) and activator (CHIR99021) of the Wnt/β -catenin signaling pathway were applied, and the effect on β-catenin and target genes for proliferation and differentiation was assessed by Western blot and RT-qPCR. CASCs express multiple early cardiac differentiation markers and are committed toward myocardial differentiation. They express several Frizzled receptors, suggesting a role for Wnt signaling in clonogenicity, proliferation, and differentiation. Wnt activation increases total and active β-catenin levels. However, this does not affect CASC proliferation or clonogenicity. Wnt inhibition upregulated early cardiac markers but could not induce mature myocardial differentiation. When CASCs are committed toward myocardial differentiation, the Wnt pathway is active and can be modulated. However, despite its role in cardiogenesis and myocardial differentiation of pluripotent stem-cell populations, our data indicate that Wnt signaling has limited effects on CASC clonogenicity, proliferation, and differentiation.

29 January 2015 in Cell Proliferation
Verified
Journal Article
Closed access
PDF file
SWS. Windmolders
S. Windmolders
LWLeen Willems
Leen Willems
ADA. Daniëls
A. Daniëls
LLL. Linsen
L. Linsen
YFY. Fanton
Y. Fanton
KHK. Hensen
K. Hensen

23 August 2016 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MHMarc Hendrikx
Marc Hendrikx
YFYanick Fanton
Yanick Fanton
LWLeen Willems
Leen Willems
ADAnnick Daniels
Annick Daniels
JDJeroen Declercq
Jeroen Declercq
JRJean-Luc Rummens
Jean-Luc Rummens
Abstract: Traditionally the heart is considered a terminally differentiated organ. However, at the beginning of this century increased mitotic activity was reported in ischemic and idiopathic dilated cardiomyopathy hearts, compared to healthy controls, underscoring the potential of regeneration after injury. Due to the presence of adult stem cells in bone marrow and their purported ability to differentiate into other cell lineages, this cell population was soon estimated to be the most suited candidate for cardiac regeneration. Clinical trials with autologous bone marrow-derived mononuclear cells, using either an intracoronary or direct intramyocardial injection approach consistently showed only minor improvement in global left ventricular ejection fraction. This was explained by their limited cardiomyogenic differentiation potential. To obtain more convincing improvement in cardiac function, based on true myocardial regeneration, the focus of research has shifted towards resident cardiac progenitor cells. Several isolation procedures have been described: the c-kit surface marker was the first to be used, however experimental research has clearly shown that c-kit+ cells only marginally contribute to regeneration post myocardial infarction. Sphere formation was used to isolate the so-called cardiosphere derived cells (CDC), and also in this cell population cardiomyogenic differentiation is a rare event. Recently a new type of stem cells derived from atrial tissue (cardiac atrial stem cells – CASCs) was identified, based on the presence of the enzyme aldehyde dehydrogenase (ALDH). Those cells significantly improve both regional and global LV ejection fraction, based on substantial engraftment and consistent differentiation into mature cardiomyocytes (98%).